Literature DB >> 29127719

Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis.

Sivesh K Kamarajah1, Timothy L Frankel2, Christopher Sonnenday2, Clifford S Cho2, Hari Nathan2.   

Abstract

BACKGROUND: Recently, the American Joint Committee on Cancer (AJCC) released its 8th edition changes to the staging system for hepatocellular cancer (HCC). We sought to validate the 8th edition staging system and compare the performance to the 7th edition using a population-based data set.
METHODS: Using the Surveillance, Epidemiology and End Results (SEER) database (1998-2013), patients undergoing resection or transplant for non-metastatic HCC were identified. Overall survival was estimated using the Kaplan-Meier method and compared using log-rank tests. Concordance indices (c-indices) were calculated from Cox proportional hazards models to evaluate discriminatory power.
RESULTS: The study included 8918 patients resected (63%) or transplanted (37%) for HCC. Nodal staging was performed in 19%, of whom 5% had positive nodes. The c-index for the AJCC 8th edition staging system was 0.60, similar to that for the 7th edition (0.59). Survival was better for solitary tumors >2 cm with vascular invasion than for multifocal tumors <5 cm (median not reached vs 57 months, P < 0.0001), although the staging system groups these tumors together as T2. For multifocal tumors ≤5 cm, those with vascular invasion had worse survival than those without (median 42 vs 50 months, P < 0.001), although the staging system draws no such distinction.
CONCLUSION: The AJCC 8th edition staging system for HCC performs similarly to the 7th edition. Future revisions should consider substratification of early HCC, specifically by distinguishing solitary tumors >2 cm from multifocal tumors ≤5 cm, and by considering the prognostic impact of vascular invasion in multifocal tumors ≤5 cm. Future studies should aim to validate these findings.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  SEER; hepatocellular cancer; staging; surgery; survival

Mesh:

Year:  2017        PMID: 29127719     DOI: 10.1002/jso.24908

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  46 in total

1.  Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management.

Authors:  Wei Xu; Fei Liu; Xianbo Shen; Ruineng Li
Journal:  J Hepatocell Carcinoma       Date:  2020-10-27

2.  Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.

Authors:  Keisuke Koroki; Sadahisa Ogasawara; Yoshihiko Ooka; Hiroaki Kanzaki; Kengo Kanayama; Susumu Maruta; Takahiro Maeda; Masayuki Yokoyama; Toru Wakamatsu; Masanori Inoue; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Shingo Nakamoto; Shin Yasui; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Satoshi Kuboki; Masayuki Ohtsuka; Masaru Miyazaki; Osamu Yokosuka; Naoya Kato
Journal:  Liver Cancer       Date:  2020-07-22       Impact factor: 11.740

3.  Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.

Authors:  Li-Ju Chen; Yun-Jau Chang; Yao-Jen Chang
Journal:  Oncologist       Date:  2020-10-03

Review 4.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

5.  Impact of Socioeconomic Factors on Prognosis and Clinical Management in Patients with Hepatocellular Carcinoma.

Authors:  Bing-Bing Su; Bao-Huan Zhou; Dou-Sheng Bai; Jian-Jun Qian; Chi Zhang; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

6.  Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis.

Authors:  Emily L Ryon; Joshua P Kronenfeld; Rachel M Lee; Adam Yopp; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Maria C Russell; Neha Goel; Nipun B Merchant; Jashodeep Datta
Journal:  J Surg Oncol       Date:  2020-10-30       Impact factor: 3.454

7.  Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments.

Authors:  Fanyu Meng; Haoyun Zhang; Haiwen Peng; Shichun Lu
Journal:  Biomed Res Int       Date:  2021-03-19       Impact factor: 3.411

8.  Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion.

Authors:  Kai Zhang; Changcheng Tao; Fan Wu; Tana Siqin; Jianxiong Wu; Weiqi Rong
Journal:  Int J Gen Med       Date:  2021-06-03

9.  Artificially engineered antiferromagnetic nanoprobes for ultra-sensitive histopathological level magnetic resonance imaging.

Authors:  Zeyu Liang; Qiyue Wang; Hongwei Liao; Meng Zhao; Jiyoung Lee; Chuang Yang; Fangyuan Li; Daishun Ling
Journal:  Nat Commun       Date:  2021-06-22       Impact factor: 14.919

10.  Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate Oncogene Correlates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.

Authors:  Mengqing Chen; Shangkun Li; Yuling Liang; Yue Zhang; Dan Luo; Wenjun Wang
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.